FURVENT

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Sep 10, 2023 → Oct 7, 2026

Cited window

Sep 10, 2023 → Oct 7, 2026

Retrieved

Oct 18, 2026

Title

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Registry

NCT05607550

Study IDs

FURMO-004 · 2022-502977-41-00

Sponsor

ArriVent BioPharma, Inc.

Collaborators

Allist Pharmaceuticals, Inc.

Design

Phase 3 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

398 actual

Start

2023-06-01 actual

Primary completion

2025-08-15 estimated

Primary endpoint

Progression Free Survival (PFS) determined by blinded independent central review (BICR)

Interventions

3 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
• –Out of scope: 2 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
• –2 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
• –Further source limits apply, so some matching discussion may be missing.
• –The report describes the sources reviewed for this edition, not the distribution of HCP opinion. Repeated appearances of the same statement do not establish independent agreement.
• –No full FURVENT results publication or protocol was available. The reported OS trend and response and investigator-assessed PFS observations lack effect sizes in the posts, limiting interpretation of clinical benefit.
• –Earlier FAVOUR observations and second-line-plus furmonertinib data provide context but cannot establish FURVENT's first-line efficacy, dose comparison or safety.
• –Matching regulatory labeling was not available for the furmonertinib doses or chemotherapy regimen. Regulatory descriptions in commentary were not independently established.
• –Some contributions came from accounts or an organization rather than confirmed individual HCPs. Sharing a linked article does not establish endorsement of its statements.
• –Dated descriptions of standard care, accrual hopes and anticipated data timing are not verification of current guidance or completed milestones.

How reports are built and checked: Methods.

Last checked for new commentary Oct 18, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.